| Bioactivity | BMS-902483 is a quinuclidine-containing spirooxazolidine that is a partial agonist at the α7 nicotinic acetylcholine receptor. BMS-902483 exhibits excellent selectivity for α7 over the highly homologous 5-HT3A receptor. BMS-902483 is generated by modifying the N-spiroiminine heterocyclic substituent. BMS-902483 improves cognitive performance in preclinical rodent models[1]. |
| Target | α7 Nicotinic receptor |
| CAS | 352519-21-2 |
| Formula | C19H25N5O3 |
| Molar Mass | 371.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |